🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521502-18-00
Authorised Phase I

A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

2025-521502-18-00 · tracked via the Priya Life Science EU tracker
Sponsor
Otsuka Pharmaceutical Development & Commercialization Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
19/09/2025
Enrollment target
32
Sites
Bulgaria

Condition studied

Tuberculosis

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521502-18-00 on CTIS ↗ ← All trials in the EU